Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

Ji, Linong; Gao, Leili; Jiang, Hongwei; Yang, Jing; Yu, Lei; Wen, Jie; Cai, Chenghang; Deng, Huan; Feng, Liqi; Song, Baili; Ma, Qingyang; Qian, Lei

Ji, Linong; Gao, Leili; Jiang, Hongwei; Yang, Jing; Yu, Lei; Wen, Jie; Cai, Chenghang; Deng, Huan; Feng, Liqi; Song, Baili; Ma, Qingyang; Qian, Lei.

Afiliação

Ji L; Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
Gao L; Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
Jiang H; The First Affiliated Hospital and Clinical Medicine College, Henan University of Science and Technology, Luoyang, China.
Yang J; Department of Endocrinology, The First Hospital of Shanxi Medical University, Taiyuan, China.
Yu L; Department of Endocrinology, Bengbu Medical College, Bengbu, China.
Wen J; Innovent Biologics, Inc., Suzhou, China.
Cai C; Innovent Biologics, Inc., Suzhou, China.
Deng H; Innovent Biologics, Inc., Suzhou, China.
Feng L; Innovent Biologics, Inc., Suzhou, China.
Song B; Innovent Biologics, Inc., Suzhou, China.
Ma Q; Innovent Biologics, Inc., Suzhou, China.
Qian L; Innovent Biologics, Inc., Suzhou, China.